Scinovex
article Open AccessTop 1% cited

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Journal of Clinical Oncology · 2008 · Vol. 26(21) · pp. 3552–3559
Jean‐Pierre PignonHélène TribodetGiorgio V. ScagliottiJean-Yves DouillardFrances A. ShepherdRichard StephensAriane DunantValter TorriRafael RosellLesley SeymourStephen SpiroEstelle RollandRoldano FossatiD. AubertKeyue DingDavid WallerThierry Le Chevalier

Abstract

Postoperative cisplatin-based chemotherapy significantly improves survival in patients with NSCLC.

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research StudiesMedicineVinorelbineInternal medicineVincaChemotherapyEtoposideHazard ratioVinca alkaloidCisplatinLung cancer

MeSH terms

AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinFemaleHumansLung NeoplasmsMaleMiddle AgedRandomized Controlled Trials as TopicChemotherapy, AdjuvantDisease-Free SurvivalKaplan-Meier Estimate

Funding

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi
  • American Society of Clinical Oncology
  • Les Laboratories Pierre Fabre
Citations
2,629
FWCI
73.31
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
Related articles
Pharmacological Activity of Vinca Alkaloids
Journal of Pharmacognosy and Phytochemistry · 2016 · 10 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.